Orthofix Medical Q4 EPS of $0.26 Misses $0.44 Estimate, Revenues Lag
Orthofix Medical reported Q4 2025 adjusted EPS of $0.26, missing the $0.44 consensus and up from $0.02 a year earlier. Quarterly revenues also trailed analyst forecasts, highlighting margin pressures as the company issues full-year 2026 financial guidance.
1. Q4 2025 Earnings Performance
Orthofix delivered adjusted earnings per share of $0.26 for the fourth quarter of 2025, falling short of the $0.44 consensus estimate while improving from $0.02 in the same period last year.
2. Revenue Shortfall and Margin Impact
The company’s Q4 revenue came in below analyst expectations, contributing to narrower margins as Orthofix navigated cost pressures and uneven procedural device demand.
3. 2026 Financial Guidance
Alongside its fourth-quarter results, Orthofix provided financial guidance for full-year 2026, outlining targets for sales growth and margin expansion driven by new product launches and operational efficiencies.